<DOC>
	<DOCNO>NCT02146066</DOCNO>
	<brief_summary>The study open-label expand access study patient vaccine manufacture Northwest Biotherapeutics ' 020221 DCVax-L GBM screening process , subsequently fail meet specific enrollment criterion . Patients receive therapy per investigator discretion ( standard care ) well active vaccine per 020221 protocol administration schedule . It estimate approximately 99 patient enroll study .</brief_summary>
	<brief_title>Expanded Access Protocol GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221</brief_title>
	<detailed_description>Patients screen protocol 020221 eligible enrollment due ) evidence disease progression pseudo-progression post chemo-radiation b ) insufficient ( &lt; 5 dos ) vaccine manufacture , DCVax-L treatment manufacture release eligible study . Treatment Schedule : Open label vaccine injection give per associate 020221 protocol . Injections give day 0 , 10 , 20 , month 2 , 4 , 8 , 12 , 18 , 24 30 . There therapeutic restriction , guideline drug administration recommend per 020221 protocol . Data collect include vaccine administration information , vaccine related adverse event . Patient MRIs collect centrally future review . Patients follow disease progression survival .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1 . ScreenFail protocol 020221 due either : Radiographic evidence disease progression pseudoprogression Baseline visit protocol 020221 , determine central image review , OR Insufficient vaccine manufacture protocol 020221 ( i.e . le 5 dos ) . 2 . Patients must KPS rating ≥70 Baseline Visit ( Visit 5 ) ( refer Appendix D , Performance Status Scales ) . 3 . Patients may receive steroid therapy part primary treatment . Steroid treatment preferably stop ; continue steroid use clinically indicate , taper 4 mg dexamethasone qd least 7 day prior first immunization . 4 . DCVaxL product manufacture release . 1 . Active uncontrolled infection , acute infection require antibiotic antifungal therapy . Antibiotic antifungal therapy complete approximately 7 day prior first immunization . 2 . Fever ≥101.5oF . If consider possibly transient , retesting allow . 3 . Unstable severe intercurrent medical condition . 4 . Females childbearing potential pregnant lactate use adequate contraception ( abstinence , surgical , hormonal double barrier , i.e . condom diaphragm ) . 020221 Baseline lab result local lab result acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>glioblastoma</keyword>
	<keyword>Brain tumor WHO grade IV</keyword>
</DOC>